The UK drugmaker also said that adverse reactions were lower among the elderly, Britain's Financial Times newspaper reported The vaccine triggers protective antibodies on T cells in older age groups.

英國製藥商還表示，老年人的不良反應較低， 英國《金融時報》報道， 疫苗會引發老年群體T細胞的保護性抗體。

T cell immunity is thought to be essential to protection against infection from the virus and could provide longer term immunity than antibodies.

T細胞免疫被認為是防止病毒感染的必要條件，可以提供比抗體更長期的免疫力。

Blood tests carried out on a set of older participants reflected data released in July which showed the vaccine did generate quote robust immune responses in healthy adults aged 18 to 55.

對一組老年參與者進行的血液測試反映了7月發佈的數據，這些數據顯示，疫苗確實在18至55歲的健康成年人中產生報價強大的免疫反應。

AstraZeneca said that it was encouraging to see the immune responses were similar between both older and younger adults.

阿斯利康表示，看到老年人和年輕人之間的免疫反應相似，令人鼓舞。

They also claimed the results further built the body of evidence for the safety and effectiveness of their drug.

他們還聲稱，該結果進一步建立了其藥物安全性和有效性的證據體系。

AstraZeneca has worked with University of Oxford researchers this year on a vaccine, and it's seen as a global front runner in the race to produce one.

阿斯利康公司今年與牛津大學的研究人員合作開發了一種疫苗，在生產疫苗的競賽中，阿斯利康公司被視為全球的領跑者。

British Health Secretary Matt Hancock said a vaccine was not yet ready, but he was preparing logistics for a possible rollout.

英國衛生大臣馬特-漢考克說，一種疫苗還沒有準備好，但他正在為可能的推廣做後勤準備。

He added he expected this to happen in the first half of 2021.

他補充說，他預計這將在2021年上半年發生。

Astra Zeneca shares rose around nor 20210.8% in early trade Monday, defying a down day for broader markets.

阿斯利康股價週一早盤上漲約也20210.8%，不畏大盤下跌。